Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer (Cancer Cell)

Quereda et al. develop a selective dual CDK12/CDK13 inhibitor that reduces the expression of core DNA damage response genes by increasing intronic polyadenylation site cleavage, resulting in DNA damage repair deficiency and conferring sensitivity to DNA-damaging agents and PARP inhibitors.